alpelisib - Profile
What are the generic drug sources for alpelisib and what is the scope of freedom to operate?
Alpelisib
is the generic ingredient in two branded drugs marketed by Novartis and is included in three NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Summary for alpelisib
| International Patents: | 75 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 3 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for alpelisib
Generic Entry Dates for alpelisib*:
Constraining patent/regulatory exclusivity:
EXPANSION OF THE INDICATION TO INCLUDE PRE AND PERIMENOPAUSAL WOMEN Dosage:
TABLET;ORAL |
Generic Entry Dates for alpelisib*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY Dosage:
TABLET;ORAL |
Generic Entry Dates for alpelisib*:
Constraining patent/regulatory exclusivity:
Dosage:
GRANULES;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for alpelisib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VIJOICE | alpelisib | GRANULE;ORAL | 218466-001 | Apr 24, 2024 | RX | Yes | Yes | 12,427,141 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | VIJOICE | alpelisib | GRANULE;ORAL | 218466-001 | Apr 24, 2024 | RX | Yes | Yes | 11,433,059 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | VIJOICE | alpelisib | GRANULE;ORAL | 218466-001 | Apr 24, 2024 | RX | Yes | Yes | 8,476,268 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novartis | VIJOICE | alpelisib | GRANULE;ORAL | 218466-001 | Apr 24, 2024 | RX | Yes | Yes | 8,227,462 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | 8,227,462 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | 8,476,268 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for alpelisib
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Piqray | alpelisib | EMEA/H/C/004804Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). | Authorised | no | no | no | 2020-07-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for alpelisib
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2017219834 | BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) | ⤷ Start Trial |
| Australia | 2022235569 | BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) | ⤷ Start Trial |
| Australia | 2024278598 | BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) | ⤷ Start Trial |
| Canada | 3013845 | METHODES POUR LE TRAITEMENT DU SPECTRE DE SURCROISSANCE LIE AU PIK3CA (METHODS FOR THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM) | ⤷ Start Trial |
| China | 109562103 | 用于治疗PIK3CA相关过度生长综合征群的方法 (BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME)) | ⤷ Start Trial |
| China | 118477075 | 用于治疗PIK3CA相关过度生长综合征群的方法 (Methods for treating PIK3CA-related overgrowth syndrome populations) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for alpelisib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2331537 | 20C1055 | France | ⤷ Start Trial | EPRODUCT NAME: ALPELISIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, REGISTRATION NO/DATE: EU/1/20/1455 20200728 |
| 2331537 | 132020000000155 | Italy | ⤷ Start Trial | PRODUCT NAME: ALPELISIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE.(PIQRAY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1455, 20200728 |
| 2331537 | SPC/GB20/059 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ALPELISIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 67359 20200324; UK EU/1/20/1455(FOR NI) 20200728; UK FURTHER MA ON IPSUM 20200728 |
| 2331537 | LUC00186 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ALPELISIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST MARKETING AUTHORISATION NUMBER AND DATE: EU/1/20/1455; 20200728 |
| 2331537 | C202030063 | Spain | ⤷ Start Trial | PRODUCT NAME: ALPELISIP O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1455; DATE OF AUTHORISATION: 20200727; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1455; DATE OF FIRST AUTHORISATION IN EEA: 20200727 |
| 2331537 | PA2020534,C2331537 | Lithuania | ⤷ Start Trial | PRODUCT NAME: ALPELISIBAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/20/1455 20200727 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Alpelisib: Investment Scenario, Market Dynamics, and Financial Trajectory
More… ↓
